NCT00387634

Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 323 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 15 Years – 68 Years
• Healthy volunteers: Accepted

Summary

evaluate safety and immunogenicity of first TBE booster and long-term immunogenicity up to 5 years after first TBE booster

Conditions

• Tick Born Encephalitis

Interventions

Type	Name	Description
BIOLOGICAL	TBE vaccine for adults	Serology blood draw.

Timeline

• Start date: 2006-09-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2006-10-13
• Last updated: 2012-11-02

Locations

1 site across 1 country: Czechia